| A | Single dose of ceftriaxone (Rocephin), 250 mg intramuscularly, or single dose of cefixime (Suprax), 400 mg orally | — | Regimen covers Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens |
| | then | | |
| Doxycycline, 100 mg orally twice daily for 10 days | | |
| B | Ciprofloxacin, 500 mg orally twice daily for 10 to 14 days | Trimethoprim/sulfamethoxazole, 160/800 mg orally twice daily for 10 to 14 days | Extend treatment for 2 weeks if patient remains symptomatic |
| | or | | |
| Levofloxacin (Levaquin), 500 to 750 mg orally daily for 10 to 14 days | | |
| C | Ciprofloxacin, 400 mg IV every 12 hours | Ceftriaxone, 1 to 2 g IV every 24 hours | Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks |
| | or | | plus | |
| Levofloxacin, 500 to 750 mg IV every 24 hours | Levofloxacin, 500 to 750 mg IV every 24 hours | |
| | | or | |
| | Piperacillin/tazobactam (Zosyn), 3.375 g IV every 6 hours | |
| D | Piperacillin/tazobactam, 3.375 g IV every 6 hours plus aminoglycosides* | Fluoroquinolone (group C) | Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks |
| | | plus | |
| | or | Aminoglycosides* | |
| Cefotaxime (Claforan), 2 g IV every 4 hours plus aminoglycosides* | | or | |
| | or | Ertapenem (Invanz), 1 g IV every 24 hours | |
| Ceftazidime (Fortaz), 2 g IV every 8 hours plus aminoglycosides* | | or | |
| | Imipenem/cilastatin (Primaxin), 500 mg IV every 6 hours | |
| | | or | |
| | Meropenem (Merrem IV), 500 mg IV every 8 hours | |
| E | Transrectal manipulation—fluoroquinolone resistance and extended spectrum beta-lactamase–producing Escherichia coli | | Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks |
| | | Carbapenems can be used if patient is unstable |
| Piperacillin/tazobactam, 3.375 g IV every 6 hours plus aminoglycosides* | Ertapenem, 1 g IV every 24 hours | If patient is stable, follow primary regimen while awaiting culture results |
| | | or | |
| | Imipenem/cilastatin, 500 mg IV every 6 hours | |
| Transurethral manipulation—Pseudomonas species | | |
| Piperacillin/tazobactam, 3.375 g IV every 6 hours† | Fluoroquinolone (group C)† | |
| | or | | or | |
| Ceftazidime, 2 g IV every 8 hours† | Imipenem/cilastatin, 500 mg IV every 6 hours | |
| | or | | or | |
| Cefipime, 2 g IV every 12 hours† | Meropenem, 500 mg IV every 8 hours | |
| Fluoroquinolone exposure—fluoroquinolone resistance | | |
| Piperacillin/tazobactam, 3.375 g IV every 6 hours† | Ceftriaxone, 1 g IV every 24 hours† | |
| | or | | or | |
| Ceftazidime, 2 g IV every 8 hours† | Ertapenem, 1 g IV every 24 hours | |
| | or | | |
| Cefepime, 2 g IV every 12 hours† | | |